

Towards the Clinical Use of Phytoplankton Carotenoid Pigments to Cure Cancer

Juin C¹, Thiéry V¹, Cadoret JP² and Picot L^{1*}

¹Université de La Rochelle, UMRi CNRS 7266 LIENSs, 17042 La Rochelle, France

²Ifremer, Laboratoire BRM/PBA, Rue de l'Île d'Yeu, 44311 Nantes, France

Beyond their major ecophysiological functions, phytoplankton pigments exert biological and pharmacological activities in human cells that allow considering their clinical use to cure various pathologies. Although much of our knowledge relating to their cell pharmacology and bioactivity has come from *in vitro* studies in cell culture models, recent *in vivo* studies have validated the potential of phytoplankton carotenoid pigments to limit inflammation and metabolic disorders, retinal diseases, degenerative diseases, tumor progression, and hepatotoxicity. Aside from these promising results, additional studies are now required to precise their pharmacokinetics, pharmacological targets, and clinical efficacy in humans. The availability of highly purified pigments at rational costs will be a milestone to set up clinical trials and develop new therapies using microalgae pigments. This short paper focuses on the great potential of phytoplankton carotenoid pigments to prevent and cure cancers.

Marine and freshwater microalgae have evolved a wide range of pigments that belong to the chlorophylls, carotenoids and phycobiliproteins families. Extensive research has proved that microalgae pigments exert significant biological and pharmacological activities in human cells. Beyond their well-known antioxidant activity, used as a commercial argument to sell algae-based cosmetics and nutraceuticals, it is now clearly established that microalgae pigments have a great potential as health nutrients to prevent cancer, as biotechnological probes for cancer diagnosis and as anticancer drugs to trigger cancer cells apoptosis, prevent tumor angiogenesis, reduce the risk of metastasis, sensitize cancer cells to chemotherapy, destroy cancer cells by tumor phototherapy and filter UV to limit cancer cells initiation. Numerous studies aiming to identify antiproliferative molecules from microalgae extracts led to the isolation of carotenoids and to the demonstration of their high antiproliferative, cytostatic, cytotoxic, and/or pro-apoptotic activity in cancer cell cultures [1,2]. As an example, our research team performed the bioguided isolation of pigments from *Dunaliella tertiolecta* and found that violaxanthin was the most antiproliferative molecule contained in *Dt* dichloromethane extract [3]. We also recently reported the strong antiproliferative activity of zeaxanthin and β -cryptoxanthin in human invasive melanoma cells, after their bioguided isolation from *Cyanophora paradoxa* ethanolic extracts [4].

Besides the purification of antiproliferative pigments [5,6], additional studies established that multiple cellular and molecular processes are affected by microalgae carotenoids. It was first demonstrated that their antioxidant activity protects against ROS-induced DNA mutations, and tissue and animals studies confirmed that most carotenoids effectively reduce the inflammatory processes initiated by carcinogenic agents, and thus prevent the risk of cancer initiation. As an example, adding peridinin in the dietary water of mice limits the development of carcinogens-induced skin tumors. Some authors also demonstrated that in addition to the cancer preventive effect associated to their antioxidant activity, some carotenoids such as fucoxanthin could trigger apoptosis in cancer cells by ROS generation. Pharmacological studies performed with fucoxanthin and various

epoxycarotenoids confirmed that they affect a multitude of molecular and cellular targets dysregulated in cancer cells (cyclin-dependent kinases, DNA polymerases, connexins, pro and antiapoptotic proteins, MAP kinases, NF- κ B, ...), and numerous studies are currently undertaken to precise the pharmacology of carotenoids, according to their high interest for human oncology. Beyond their cytotoxic activity, some carotenoids also inhibit the tumor neovascularization and the metastatic potential of cancer cells, reverse multi-drug resistance in cancer cells treated with chemotherapeutic agents, and alleviates the deleterious side effects of cytotoxic drugs. Fucoxanthin was particularly well studied and its clinical efficacy to cure cancers from various tissular origins is validated in animal models, and should soon be validated in humans.

As a conclusion, it is obvious that microalgae carotenoids have a key role to play in clinical oncology and cancer nutritional prevention, according to their remarkable pharmacological activities. In addition to synthesizing most of the oxygen that we breathe, microalgae could thus have a great potential to help us fighting the second cause of death in developed countries.

References

1. Mimouni V, Ulmann L, Pasquet V, Mathieu M, Picot L, et al. (2012) The potential of microalgae for the production of bioactive molecules of pharmaceutical interest. *Curr Pharm Biotechnol* 13: 2733-2750.
2. Gagez AL, Thiéry V, Pasquet V, Cadoret JP, Picot L (2012) Epoxycarotenoids and cancer: Review. *Current Bioactive compounds* 8: 109-141.
3. Pasquet V, Morrisset P, Ihammouine S, Chepied A, Aumailley L, et al. (2011) Antiproliferative activity of violaxanthin isolated from bioguided fractionation of *Dunaliella tertiolecta* extracts. *Mar Drugs* 9: 819-831.
4. Baudalet PH, Gagez AL, Bérard JN, Juin C, Bridiau N, et al. (2013) Antiproliferative activity of *Cyanophora paradoxa* pigments in melanoma, breast and lung cancer cells. *Mar Drugs* 11: 4390-4406.
5. Serive B, Kaas R, Bérard JB, Pasquet V, Picot L, et al. (2012) Selection and optimisation of a method for efficient metabolites extraction from microalgae. *Bioresour Technol* 124: 311-320.
6. Pasquet V, Chérouvrier JR, Farhat F, Thiéry V, Piot JM, et al. (2011) Study on the microalgal pigments extraction process: Performance of microwave assisted extraction. *Process Biochem* 46: 59-67.

*Corresponding author: Laurent Picot, Université de La Rochelle, UMRi CNRS 7266 LIENSs, 17042 La Rochelle, France, Tel: +(33)5.46.45.82.20; Fax : +(33)5.46.45.82.65; E-mail: lpicot@univ-lr.fr

Received December 03, 2013; Accepted December 05, 2013; Published December 09, 2013

Citation: Juin C, Thiéry V, Cadoret JP, Picot L (2013) Towards the Clinical Use of Phytoplankton Carotenoid Pigments to Cure Cancer. *Oceanography* 1: e105. doi:10.4172/2332-2632.1000e105

Copyright: © 2013 Juin C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.